CPT code 81216: BRCA2 sequencing, full gene sequence2026 Medicare lab fee · Clinical Laboratory Fee Schedule
Full-sequence BRCA2 analysis identifies inherited variants associated with breast and ovarian cancer susceptibility in patients undergoing hereditary cancer risk evaluation.
Medicare pays $185.12 for 81216 under the 2026 Clinical Laboratory Fee Schedule: one national amount, the same in every state and setting.
Medicare lab fee · CLFS 2026 Q4
National CLFS amount
$185.12
In effect since Jan 1, 2026. The same amount in every state, payment locality and setting.
- Geographic adjustment
- None
- Office vs facility
- Same
- Since 2020
- Unchanged
- CMS updates
- Quarterly
Medicare pays the lesser of the lab’s charge and this amount. Patients usually owe no Part B deductible or coinsurance for covered clinical lab tests.
On this page 8 sections
What 81216 covers
This assay examines the full BRCA2 gene sequence for inherited variants associated with hereditary breast and ovarian cancer susceptibility. Genetics professionals, oncologists, and other clinicians may order it when evaluating a patient’s personal or family cancer history or assessing inherited risk in a relative. The laboratory sequences patient DNA and reports detected variants with clinical interpretation.
Report 81216 for full-sequence BRCA2 analysis, rather than a targeted test for a previously identified familial variant or a limited BRCA1/2 variant assay. Medicare pays this test only through the CLFS. The 2026 national amount is $185.12, unchanged since 2020. One national rate applies across localities, without geographic or office/facility adjustment. The test is excluded from the physician fee schedule.
This summary was written with AI assistance from CMS Clinical Laboratory Fee Schedule data. Amounts on this page come directly from CMS files.
How Medicare pays 81216
Clinical lab tests aren’t priced like physician services. They’re paid from their own fee schedule, with its own rules. See the whole lab fee schedule.
One national amount
CMS sets a single Clinical Laboratory Fee Schedule amount for 81216. There’s no geographic (GPCI) adjustment, so it pays the same in every state and payment locality.
No office or facility rate
Lab tests aren’t built from relative value units, so there’s no office and facility split: the place of service doesn’t change the CLFS amount.
Updated every quarter
CMS republishes the CLFS each quarter. New tests, often proprietary laboratory analyses (PLA codes), join during the year; existing amounts are updated each January.
Excluded from the physician fee schedule
The physician fee schedule lists 81216 with status X (excluded by statute), so the test itself is paid only from the CLFS.
81216 on the lab fee schedule since 2020
81216 · CLFS 2026 Q4 (current)
$185.12
Unchanged since Jan 1, 2020
27 quarterly CLFS releases on file, first CLFS 2020 Q1. A code missing from a quarter wasn’t on that release.
81216 compared with similar tests
- 81217BRCA2 testingKnown familial variant$375.25
- 81217 targets a previously identified familial BRCA2 variant. Choose 81216 when the laboratory analyzes the full BRCA2 sequence.
- 81212BRCA testingThree specified variants$440.00
- 81212 is for selected BRCA1/2 variants, not full BRCA2 sequencing. The assay actually performed determines which code describes the service.
- 81162BRCA1/2 testingFull sequence and rearrangements$1,824.88
- 81162 covers combined BRCA1 and BRCA2 sequencing with deletion/duplication analysis. 81216 represents full-sequence analysis of BRCA2 alone.
81216 billing questions
Does 81216 include BRCA1 analysis?
No. 81216 analyzes BRCA2 only. Code 81212 covers selected BRCA1/2 variants, while 81162 covers combined BRCA1 and BRCA2 sequencing with deletion/duplication analysis.
When should 81217 be used instead?
Use 81217 for targeted testing of a known familial BRCA2 variant. Use 81216 when the full BRCA2 sequence is analyzed.
How does 81216 differ from 81212?
81216 analyzes the full BRCA2 sequence. 81212 represents a limited assay for selected BRCA1/2 variants.
How does Medicare pay for 81216?
Medicare pays the laboratory test through the CLFS at one national rate. The code is excluded from the physician fee schedule.
Where this amount comes from
FeeBase reads lab amounts directly from the CMS Clinical Laboratory Fee Schedule file for the quarter: one row per code, with its payment indicator and national amount. Contractor-priced tests are labeled, never given a made-up amount. Amounts are Medicare payment limits, not a patient’s bill or a commercial rate.
CMS CLFS 2026 Q4 · effective Oct 1, 2026 through the day before Jan 1, 2027
Show the CMS file line behind this amount
Fee sheets · Coming soon
Put 81216 and the rest of your codes on one sheet
Your codes at your locality, with payer contracts beside Medicare.
Join the waitlist